Effects of Recombinant Human Brain Natriuretic Peptide on Atrial Fibrillation After Coronary Artery Bypass Grafting

Abstract

:Previous studies reported that the use of natriuretic peptides (NPs) can effectively decrease arrhythmias. However, there is a lack of clinical evidence that recombinant human brain natriuretic peptide (rh-BNP) inhibits postoperative atrial fibrillation (POAF). This cohort aims to assess the effect of rh-BNP on POAF. This study retrospectively reviewed patients who underwent isolated coronary artery bypass grafting from January 2018 to January 2021. Patients were divided into 2 groups according to whether they received rh-BNP therapy within 5 days after surgery. A total of 1153 patients met the inclusion and exclusion criteria, of which 54 received rh-BNP therapy within 5 days. After propensity score matching, 53 patients were treated with rh-BNP, and 148 patients were not treated with rh-BNP. The incidence of POAF was lower in rh-BNP group than non-rh-BNP group (18.9% vs. 37.2%, odds ratio = 0.393, 95% confidence interval, 0.183–0.845, P = 0.017). There was no significant difference in the occurrence of ventricular arrhythmia (P = 0.4), hypotension (P = 0.763), and the risk of death (P = 0.14). rh-BNP could significantly reduce the occurrence of POAF after coronary artery bypass grafting, and rh-BNP did not increase the risk of ventricular arrhythmia, hypotension, and death. Accordingly, rh-BNP could be a potential safe medicine for preventing POAF.

Efficacy of recombinant human brain natriuretic peptide as an adjuvant therapy for severe heart failure, and its impact on oxidative stress and quality of life in patients

“…Overall, the results indicate that recombinant human brain natriuretic peptide improves patients' cardiac functions and this result is in lines with previous studies [21]. The reason may be related to the fact that recombinant human brain natriuretic peptide selectively dilates pulmonary capillaries and pulmonary veins and reduces the resistance and pressure of pulmonary circulation [22,23].…”

Should We Consider Recombinant Human Brain Natriuretic Peptide to Prevent Postoperative Atrial Fibrillation?

“…11 A clear and strong example of inhibition of this pathophysiological pathway is sacubitril use in heart failure, an inhibitor of neprilysin which, combined with valsartan, has proved safe and effective in reducing mortality and hospitalization. 12 In the current issue of the Journal, Yangyan Wei et al 13 aimed at appraising in a retrospective cohort study the role of rh-BNP in decreasing POAF (Fig. 1).…”

“…In the current issue of the Journal, Yangyan Wei et al 13 aimed at appraising in a retrospective cohort study the role of rh-BNP in decreasing POAF (Fig. 1).…”